M. Flynn

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

R. Minter, A. Sandercock, L. Jermutus, 2015, Molecular Cancer.

Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency

E. Hurt, E. Fearon, R. Hollingsworth, 2017, Oncotarget.

Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis

D. Kass, M. Flynn, E. S. Baker, 2015 .

Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

Paul G. Hynes, E. Hurt, Ruoyan Chen, 2018, Leukemia.

Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

R. Minter, L. Jermutus, A. Karlsson, 2013, Molecular Cancer.

Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies.

S. Bigner, M. Flynn, W. Johnston, 1993, Acta cytologica.

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

R. Minter, A. Sandercock, L. Jermutus, 2015, Molecular Cancer.

Multiple atypical nevi: a cutaneous marker of germ cell tumors.

J. Grygiel, J. Zalcberg, D. Raghavan, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma

E. Hurt, Ruoyan Chen, Y. Tai, 2017 .

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers

E. Hurt, M. Rebelatto, R. Tammali, 2018, Blood.